Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 and Atezolizumab in Urothelial Carcinoma
NCT03208712Phase 1Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Nov 2017
- Primary completion
- Aug 2018
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of radium-223 dichloride in urothelial carcinoma (UC), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Percent of Patients that respond to Treatment up to 52 weeks. Started Nov 2017; status: terminated.
02
Drugs
radium-223 dichloride
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03208712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03208712.